Abstract
Introduction
In the diagnostic assessment of autoimmune encephalitis (AE) associated with antineural antibody (Ab) imaging with 18F-fluorodeoxyglucose (FDG), positron emission tomography (PET) was initially only used to screen for occult malignancies in paraneoplastic cases. Today accumulating evidence also supports the use of PET imaging for the objective assessment of metabolic changes in the brain of patients with AE. On the other hand, magnetic resonance imaging (MRI) of the brain reveals a variable picture depending on the specific syndrome and associated antibody, and may be normal in a sizable proportion of patients.
Acquisition of evidence
Among all the articles retrieved, we selected only studies and case series describing 18F-PET/CT, or multimodal imaging assessments (with both PET/CT and MRI performed in the same patient) on at least five patients with AE confirmed by the presence of antineural Ab. Studies describing MRI but not PET/CT findings on at least 20 cases were also included to strengthen the morphological considerations.
Summary of evidence
We summarize the findings in the literature, commenting on studies involving the use of FDG-PET/CT in patients with AE, focusing on the added value and unsolved issues of using FDG-PET as opposed to MRI, and discussing them in the context of the available diagnostic criteria for AE. We also describe neuroimaging (PET and MRI) differences between AE with Ab against surface antigens vs AE with Ab against intracellular antigens. The timing of neuroimaging after the onset of symptoms is also considered.
Conclusions
From a systematic review of the literature, it seems that some specific metabolic patterns correlate with the presence of specific Ab, such as a cerebral posterior hypometabolism in anti-NMDAR encephalitis, and a mesiotemporal hypermetabolism (associated with hyperintensities and swollen structures on MRI T2) in encephalitis with LGI1 and onconeural Ab. To ascertain the prognostic value of FDG-PET and its role in driving therapy, larger (preferably longitudinal) studies are needed on age-matched, untreated patients with the same Ab status, who undergo imaging at a similar time after the onset of their symptoms. This would enable a systematic correlation between MRI and FDG-PET findings, and help to clarify a number of unsolved clinical and technical issues.
Similar content being viewed by others
References
Corsellis JA, Goldberg GJ, Norton AR (1968) “Limbic encephalitis” and its association with carcinoma. Brain 91:481–496
Dalmau J (2016) NMDA receptor encephalitis and other antibody-mediated disorders of the synapse: the 2016 Cotzias lecture. Neurology 87:2471–2482
Zuliani L, Graus F, Giometto B, Bien C, Vincent A (2012) Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry 83:638–645
Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T et al (2016) A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol 15:391–404
Baumgartner A, Rauer S, Mader I, Meyer PT (2013) Cerebral FDG-PET and MRI findings in autoimmune limbic encephalitis: correlation with autoantibody types. J Neurol 260:2744–2753
Wegner F, Wilke F, Raab P, Ben Tayeb S, Boeck A-L, Haense C et al (2014) Anti-leucine rich glioma inactivated 1 protein and anti-N-methyl-d-aspartate receptor encephalitis show distinct patterns of brain glucose metabolism in 18F-fluoro-2-deoxy-d-glucose positron emission tomography. BMC Neurol 14:136
Lagarde S, Lepine A, Caietta E, Pelletier F, Boucraut J, Chabrol B et al (2016) Cerebral (18)fluorodeoxy-glucose positron emission tomography in paediatric anti N-methyl-d-aspartate receptor encephalitis: a case series. Brain Dev 38:461–470
Leypoldt F, Buchert R, Kleiter I, Marienhagen J, Gelderblom M, Magnus T et al (2012) Fluorodeoxyglucose positron emission tomography in anti-N-methyl-d-aspartate receptor encephalitis: distinct pattern of disease. J Neurol Neurosurg Psychiatry 83:681–686
Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E et al (2018) Decreased occipital lobe metabolism by FDG-PET/CT: An anti-NMDA receptor encephalitis biomarker. Neurol Neuroimmunol Neuroinflamm 5:e413
Yuan J, Guan H, Zhou X, Niu N, Li F, Cui L et al (2016) Changing brain metabolism patterns in patients with ANMDARE: serial 18F-FDG PET/CT findings. Clin Nucl Med 41:366–370
Wang R, Lai X-H, Liu X, Li Y-J, Chen C, Li C, et al. Brain magnetic resonance-imaging findings of anti-N-methyl-d-aspartate receptor encephalitis: a cohort follow-up study in Chinese patients. J Neurol. 2017. http://www.ncbi.nlm.nih.gov/pubmed/29249055
Celicanin M, Blaabjerg M, Maersk-Moller C, Beniczky S, Marner L, Thomsen C et al (2017) Autoimmune encephalitis associated with voltage-gated potassium channels-complex and leucine-rich glioma-inactivated 1 antibodies—a national cohort study. Eur J Neurol 24:999–1005
Shin Y-W, Lee S-T, Shin J-W, Moon J, Lim J-A, Byun J-I et al (2013) VGKC-complex/LGI1-antibody encephalitis: clinical manifestations and response to immunotherapy. J Neuroimmunol 265:75–81
Chen Y, Xing X-W, Zhang J-T, Wang R-X, Zhao W, Tan Q-C et al (2016) Autoimmune encephalitis mimicking sporadic Creutzfeldt-Jakob disease: a retrospective study. J Neuroimmunol 295–296:1–8
Newey CR, Sarwal A, Hantus S (2016) [(18)F]-fluoro-deoxy-glucose positron emission tomography scan should be obtained early in cases of autoimmune encephalitis. Autoimmun Dis 2016:9450452
Kotsenas AL, Watson RE, Pittock SJ, Britton JW, Hoye SL, Quek AML et al (2014) MRI findings in autoimmune voltage-gated potassium channel complex encephalitis with seizures: one potential etiology for mesial temporal sclerosis. AJNR Am J Neuroradiol 35:84–89
Finke C, Prüss H, Heine J, Reuter S, Kopp UA, Wegner F et al (2017) Evaluation of cognitive deficits and structural hippocampal damage in encephalitis with leucine-rich, glioma-inactivated 1 antibodies. JAMA Neurol 74:50–59
Probasco JC, Solnes L, Nalluri A, Cohen J, Jones KM, Zan E et al (2017) Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm 4:e352
Solnes LB, Jones KM, Rowe SP, Pattanayak P, Nalluri A, Venkatesan A et al (2017) Diagnostic value of 18F-FDG PET/CT versus MRI in the setting of antibody-specific autoimmune encephalitis. J Nucl Med 58:1307–1313
Fisher RE, Patel NR, Lai EC, Schulz PE (2012) Two different 18F-FDG brain PET metabolic patterns in autoimmune limbic encephalitis. Clin Nucl Med 37:e213–e218
Ances BM, Vitaliani R, Taylor RA, Liebeskind DS, Voloschin A, Houghton DJ et al (2005) Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain 128:1764–1777
Kim T-J, Lee S-T, Shin J-W, Moon J, Lim J-A, Byun J-I et al (2014) Clinical manifestations and outcomes of the treatment of patients with GABAB encephalitis. J Neuroimmunol 270:45–50
Constantinescu R, Krýsl D, Bergquist F, Andrén K, Malmeström C, Asztély F et al (2016) Cerebrospinal fluid markers of neuronal and glial cell damage to monitor disease activity and predict long-term outcome in patients with autoimmune encephalitis. Eur J Neurol 23:796–806
Malter MP, Helmstaedter C, Urbach H, Vincent A, Bien CG (2010) Antibodies to glutamic acid decarboxylase define a form of limbic encephalitis. Ann Neurol 67:470–478
Dalmau J, Graus F, Villarejo A, Posner JB, Blumenthal D, Thiessen B et al (2004) Clinical analysis of anti-Ma2-associated encephalitis. Brain 127:1831–1844
Masangkay N, Basu S, Moghbel M, Kwee T, Alavi A (2014) Brain 18F-FDG-PET characteristics in patients with paraneoplastic neurological syndrome and its correlation with clinical and MRI findings. Nucl Med Commun 35:1038–1046
Gultekin SH, Rosenfeld MR, Voltz R, Eichen J, Posner JB, Dalmau J (2000) Paraneoplastic limbic encephalitis: neurological symptoms, immunological findings and tumour association in 50 patients. Brain 123(Pt 7):1481–1494
Urbach H, Soeder BM, Jeub M, Klockgether T, Meyer B, Bien CG (2006) Serial MRI of limbic encephalitis. Neuroradiology 48:380–386
Morbelli S, Arbizu J, Booij J, Chen M-K, Chetelat G, Cross DJ et al (2017) The need of standardization and of large clinical studies in an emerging indication of [18F]FDG PET: the autoimmune encephalitis. Eur J Nucl Med Mol Imaging 44:353–357
Cecchin D, Barthel H, Poggiali D, Cagnin A, Tiepolt S, Zucchetta P et al (2017) A new integrated dual time-point amyloid PET/MRI data analysis method. Eur J Nucl Med Mol Imaging 44:2060–2072
Kojima G, Inaba M, Bruno MK (2014) PET-positive extralimbic presentation of anti-glutamic acid decarboxylase antibody-associated encephalitis. Epileptic Disord. 16:358–361
Basu S, Alavi A (2008) Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol 10:131–137
Heine J, Prüss H, Bartsch T, Ploner CJ, Paul F, Finke C (2015) Imaging of autoimmune encephalitis—relevance for clinical practice and hippocampal function. Neuroscience 309:68–83
van Coevorden-Hameete MH, de Graaff E, Titulaer MJ, Hoogenraad CC, Sillevis Smitt PAE (2014) Molecular and cellular mechanisms underlying anti-neuronal antibody mediated disorders of the central nervous system. Autoimmun Rev 13:299–312
Plantone D, Renna R, Grossi D, Plantone F, Iorio R (2013) Teaching NeuroImages: basal ganglia involvement in facio-brachial dystonic seizures associated with LGI1 antibodies. Neurology 80:e183–e184
Lee BY, Newberg AB, Liebeskind DS, Kung J, Alavi A (2004) FDG-PET findings in patients with suspected encephalitis. Clin Nucl Med 29:620–625
Bien CG, Vincent A, Barnett MH, Becker AJ, Blümcke I, Graus F et al (2012) Immunopathology of autoantibody-associated encephalitides: clues for pathogenesis. Brain 135:1622–1638
García Vicente AM, Delgado-Bolton RC, Amo-Salas M, López-Fidalgo J, Caresia Aróztegui AP, García Garzón JR et al (2017) 18F-fluorodeoxyglucose positron emission tomography in the diagnosis of malignancy in patients with paraneoplastic neurological syndrome: a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging 44:1575–1587
Trevino-Peinado C, Arbizu J, Irimia P, Riverol M, Martínez-Vila E (2015) Monitoring the effect of immunotherapy in autoimmune limbic encephalitis using 18F-FDG PET. Clin Nucl Med 40:e441–e443
Fulham MJ, Brunetti A, Aloj L, Raman R, Dwyer AJ, Di Chiro G (1995) Decreased cerebral glucose metabolism in patients with brain tumors: an effect of corticosteroids. J Neurosurg 83:657–664
Morbelli S, Garibotto V, Van De Giessen E, Arbizu J, Chételat G, Drezgza A et al (2015) A Cochrane review on brain [18F]FDG PET in dementia: limitations and future perspectives. Eur J Nucl Med Mol Imaging 42:1487–1491
Herholz K, Salmon E, Perani D, Baron JC, Holthoff V, Frölich L et al (2002) Discrimination between Alzheimer dementia and controls by automated analysis of multicenter FDG PET. Neuroimage 17:302–316
Dodich A, Cerami C, Iannaccone S, Marcone A, Alongi P, Crespi C et al (2016) Neuropsychological and FDG-PET profiles in VGKC autoimmune limbic encephalitis. Brain Cogn 108:81–87
Solomon T, Michael BD, Smith PE, Sanderson F, Davies NWS, Hart IJ et al (2012) Management of suspected viral encephalitis in adults—association of british neurologists and british infection association national guidelines. J Infect 64:347–373
Bastiaansen AEM, van Sonderen A, Titulaer MJ (2017) Autoimmune encephalitis with anti-leucine-rich glioma-inactivated 1 or anti-contactin-associated protein-like 2 antibodies (formerly called voltage-gated potassium channel-complex antibodies). Curr Opin Neurol 30:302–309
van Sonderen A, Thijs RD, Coenders EC, Jiskoot LC, Sanchez E, de Bruijn MAAM et al (2016) Anti-LGI1 encephalitis: clinical syndrome and long-term follow-up. Neurology 87:1449–1456
Joubert B, Saint-Martin M, Noraz N, Picard G, Rogemond V, Ducray F et al (2016) Characterization of a subtype of autoimmune encephalitis with anti-contactin-associated protein-like 2 antibodies in the cerebrospinal fluid, prominent limbic symptoms, and seizures. JAMA Neurol 73:1115–1124
van Sonderen A, Ariño H, Petit-Pedrol M, Leypoldt F, Körtvélyessy P, Wandinger K-P et al (2016) The clinical spectrum of Caspr2 antibody-associated disease. Neurology 87:521–528
Lancaster E, Lai M, Peng X, Hughes E, Constantinescu R, Raizer J et al (2010) Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol 9:67–76
Höftberger R, van Sonderen A, Leypoldt F, Houghton D, Geschwind M, Gelfand J et al (2015) Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Neurology. 84:2403–2412
Spatola M, Petit-Pedrol M, Simabukuro MM, Armangue T, Castro FJ, Barcelo Artigues MI et al (2017) Investigations in GABAA receptor antibody-associated encephalitis. Neurology 88:1012–1020
Flanagan EP, Kotsenas AL, Britton JW, McKeon A, Watson RE, Klein CJ et al (2015) Basal ganglia T1 hyperintensity in LGI1-autoantibody faciobrachial dystonic seizures. Neurol Neuroimmunol Neuroinflamm 2:e161
Vitaliani R, Mason W, Ances B, Zwerdling T, Jiang Z, Dalmau J (2005) Paraneoplastic encephalitis, psychiatric symptoms, and hypoventilation in ovarian teratoma. Ann Neurol 58:594–604
Miller TD, Chong TT-J, Aimola Davies AM, Ng TWC, Johnson MR, Irani SR et al (2017) Focal CA3 hippocampal subfield atrophy following LGI1 VGKC-complex antibody limbic encephalitis. Brain. 140:1212–1219
Iizuka T, Yoshii S, Kan S, Hamada J, Dalmau J, Sakai F et al (2010) Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J. Neurol. 257:1686–1691
Park S, Choi H, Cheon GJ, Wook Kang K, Lee DS (2015) 18F-FDG PET/CT in anti-LGI1 encephalitis: initial and follow-up findings. Clin Nucl Med 40:156–158
Funding
This study was not funded by any grants.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
DC received consultant honoraria and a liberal donation from Piramal Imaging irrelevant to the aims of the paper. The other authors have no conflicts of interest to disclose.
Statement of human rights
Being a review, this statement is not mandatory.
Rights and permissions
About this article
Cite this article
Morbelli, S., Zoccarato, M., Bauckneht, M. et al. 18F-FDG-PET and MRI in autoimmune encephalitis: a systematic review of brain findings. Clin Transl Imaging 6, 151–168 (2018). https://doi.org/10.1007/s40336-018-0275-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40336-018-0275-x